Currently predicting for Thu, 4 Jun 2026

ALT Prediction Chart

ALT Predictions History

Latest community submissions for ALT.
Predictor Target Session Target Price Result Direction Accuracy Score
Feb 17, 2026 $4.68 +3.37% $4.50 X 95.94% 0
Feb 17, 2026 $4.63 +2.11% $4.50 X 97.21% 0
Feb 17, 2026 $4.53 +0.00% $4.50 V 99.33% 4
Dec 10, 2025 $5.38 -2.45% $5.43 V 99.08% 2
Dec 10, 2025 $5.43 -1.53% $5.43 V 99.99% 10
Dec 10, 2025 $9.50 +69.34% $5.43 X 24.88% 0
Oct 29, 2025 $3.99 -1.84% $4.00 V 99.63% 5
Oct 29, 2025 $4.01 -1.15% $4.00 V 99.67% 5
Oct 29, 2025 Bullish $4.00 X 0
Oct 21, 2025 $4.12 +3.00% $4.04 V 98.02% 1
Click to get the best stock tips daily for free!
Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for ALT with a full price path, not just a one-day call.
  • Price path
  • Approved predictor
  • 3-month horizon
ABOUT ALTIMMUNE, INC.
Altimmune
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinica...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE